REN and metabolic dysfunction-associated steatohepatitis: Previous studies have also reported that RAAS inhibitors suppress the progression of liver fibrosis [38,39,40] and that direct renin inhibitors and selective aldosterone inhibitors suppress liver fibrosis progression in nonalcoholic steatohepatitis (NASH) [41,42].